{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01489267",
      "OrgStudyIdInfo": {
        "OrgStudyId": "20111031SCA"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "20111031limin",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "neuralstemcell"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "General Hospital of Chinese Armed Police Forces",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation",
      "OfficialTitle": "The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Transplantation in Hereditary Cerebellar Ataxia Patients",
      "Acronym": "SCA"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2012",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Enrolling by invitation",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 2013",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 2014",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "October 30, 2011",
      "StudyFirstSubmitQCDate": "December 8, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 9, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "June 18, 2012",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 20, 2012",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "General Hospital of Chinese Armed Police Forces",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Hereditary cerebellar ataxia is a type of autosomal dominant genetic disease, lesions mainly involving the cerebellum, but the spinal cord and cranial nerves may also be some involvement. A total of 20 molecularly diagnosed SCA1 patients divided in two groups. One group accepted for the treatment of stem cell transplantation,the other group will be the control. Purpose of this project to prove that allogeneic umbilical cord mesenchymal stem cells are applied to clinical safely, and in the treatment of hereditary cerebellar ataxia is valid.",
      "DetailedDescription": "After admission the patients accepted transplantation would receive physical examination, blood and urine tests, electrocardiogram, electrophysiologic study;evaluation of SCA1 symptoms (balance, walking, dexterity, tremor, memory, mood and concentration),then stem cell therapy：after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The control only receive evaluation of SCA1 symptoms ."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Hereditary Cerebellar Ataxia."
        ]
      },
      "KeywordList": {
        "Keyword": [
          "cerebellar ataxia",
          "hereditary disease",
          "stem cell"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Control group",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy."
          },
          {
            "ArmGroupLabel": "Stem cell transplantation",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "10 patients in the group accept stem cell transplantation.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: stem cell transplantation"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "stem cell transplantation",
            "InterventionDescription": "The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Stem cell transplantation"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Cell therapy."
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "blood test",
            "PrimaryOutcomeDescription": "white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification",
            "PrimaryOutcomeTimeFrame": "within one week before transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "Nerve functional evaluation",
            "PrimaryOutcomeDescription": "Timed-up-and-go test ,5 minutes down-and-up test\nICARS score\nModified Falls Efficacy Scale\nBerg balance assessment\n\nTremor Rating Scale:\n\nPart A - Tremor location/severity rating\nPart B -Handwriting and drawings\nPart C - Functional disabilities resulting from tremor\nQuestionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)",
            "PrimaryOutcomeTimeFrame": "within one week before transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "blood test",
            "PrimaryOutcomeDescription": "white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification",
            "PrimaryOutcomeTimeFrame": "1 month after transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "blood test",
            "PrimaryOutcomeDescription": "white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification",
            "PrimaryOutcomeTimeFrame": "3 months after transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "blood test",
            "PrimaryOutcomeDescription": "white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification",
            "PrimaryOutcomeTimeFrame": "6 months after transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "blood test",
            "PrimaryOutcomeDescription": "white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification",
            "PrimaryOutcomeTimeFrame": "12 months after transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "Nerve functional evaluation",
            "PrimaryOutcomeDescription": "Timed-up-and-go test ,5 minutes down-and-up test\nICARS score\nModified Falls Efficacy Scale\nBerg balance assessment\n\nTremor Rating Scale:\n\nPart A - Tremor location/severity rating\nPart B -Handwriting and drawings\nPart C - Functional disabilities resulting from tremor\nQuestionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)",
            "PrimaryOutcomeTimeFrame": "1 month after transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "Nerve functional evaluation",
            "PrimaryOutcomeDescription": "Timed-up-and-go test ,5 minutes down-and-up test\nICARS score\nModified Falls Efficacy Scale\nBerg balance assessment\n\nTremor Rating Scale:\n\nPart A - Tremor location/severity rating\nPart B -Handwriting and drawings\nPart C - Functional disabilities resulting from tremor\nQuestionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)",
            "PrimaryOutcomeTimeFrame": "3 months after transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "Nerve functional evaluation",
            "PrimaryOutcomeDescription": "Timed-up-and-go test ,5 minutes down-and-up test\nICARS score\nModified Falls Efficacy Scale\nBerg balance assessment\n\nTremor Rating Scale:\n\nPart A - Tremor location/severity rating\nPart B -Handwriting and drawings\nPart C - Functional disabilities resulting from tremor\nQuestionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)",
            "PrimaryOutcomeTimeFrame": "6 months after transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "Nerve functional evaluation",
            "PrimaryOutcomeDescription": "Timed-up-and-go test ,5 minutes down-and-up test\nICARS score\nModified Falls Efficacy Scale\nBerg balance assessment\n\nTremor Rating Scale:\n\nPart A - Tremor location/severity rating\nPart B -Handwriting and drawings\nPart C - Functional disabilities resulting from tremor\nQuestionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)",
            "PrimaryOutcomeTimeFrame": "12 months after transplantation"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Urinal test",
            "SecondaryOutcomeDescription": "proteinum、akaryocyte、α1- microglobulin、β2- microglobulin",
            "SecondaryOutcomeTimeFrame": "within one week before transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Electrophysiology examination",
            "SecondaryOutcomeDescription": "somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)",
            "SecondaryOutcomeTimeFrame": "within one week before transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Urinal test",
            "SecondaryOutcomeDescription": "proteinum、akaryocyte、α1- microglobulin、β2- microglobulin",
            "SecondaryOutcomeTimeFrame": "1 month after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Urinal test",
            "SecondaryOutcomeDescription": "proteinum、akaryocyte、α1- microglobulin、β2- microglobulin",
            "SecondaryOutcomeTimeFrame": "3 months after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Urinal test",
            "SecondaryOutcomeDescription": "proteinum、akaryocyte、α1- microglobulin、β2- microglobulin",
            "SecondaryOutcomeTimeFrame": "6 months after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Urinal test",
            "SecondaryOutcomeDescription": "proteinum、akaryocyte、α1- microglobulin、β2- microglobulin",
            "SecondaryOutcomeTimeFrame": "12 months after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Electrophysiology examination",
            "SecondaryOutcomeDescription": "somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)",
            "SecondaryOutcomeTimeFrame": "1 month after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Electrophysiology examination",
            "SecondaryOutcomeDescription": "somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)",
            "SecondaryOutcomeTimeFrame": "3 months after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Electrophysiology examination",
            "SecondaryOutcomeDescription": "somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)",
            "SecondaryOutcomeTimeFrame": "6 months after transplantation"
          },
          {
            "SecondaryOutcomeMeasure": "Electrophysiology examination",
            "SecondaryOutcomeDescription": "somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)",
            "SecondaryOutcomeTimeFrame": "12 months after transplantation"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\n18-65 years of age\nMolecularly diagnosed SCA1\n\nExclusion Criteria:\n\nCognitively impaired individuals\nSchizophrenics\nPatients with severe kidney and liver disease, epilepsy, heart disease, pulmonary disease, cardiac arrhythmia, diabetes insipidus, leukemia and some other central neural disease (such as Parkinson disease, accidence of brain vascular et al)\nAge less than 18 years, age greater than 65 years",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Yihua An, doctor",
            "OverallOfficialAffiliation": "director of neural stem cell transplantation department in general hospital of chinese armed police forces",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Yihua An",
            "LocationCity": "Beijing",
            "LocationCountry": "China"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001259",
            "ConditionMeshTerm": "Ataxia"
          },
          {
            "ConditionMeshId": "D000002524",
            "ConditionMeshTerm": "Cerebellar Ataxia"
          },
          {
            "ConditionMeshId": "D000013132",
            "ConditionMeshTerm": "Spinocerebellar Degenerations"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000020820",
            "ConditionAncestorTerm": "Dyskinesias"
          },
          {
            "ConditionAncestorId": "D000009461",
            "ConditionAncestorTerm": "Neurologic Manifestations"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000002526",
            "ConditionAncestorTerm": "Cerebellar Diseases"
          },
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000013118",
            "ConditionAncestorTerm": "Spinal Cord Diseases"
          },
          {
            "ConditionAncestorId": "D000020271",
            "ConditionAncestorTerm": "Heredodegenerative Disorders, Nervous System"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3717",
            "ConditionBrowseLeafName": "Ataxia",
            "ConditionBrowseLeafAsFound": "Cerebellar Ataxia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4925",
            "ConditionBrowseLeafName": "Cerebellar Ataxia",
            "ConditionBrowseLeafAsFound": "Cerebellar Ataxia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M15081",
            "ConditionBrowseLeafName": "Spinocerebellar Degenerations",
            "ConditionBrowseLeafAsFound": "Hereditary Cerebellar Ataxia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21663",
            "ConditionBrowseLeafName": "Spinocerebellar Ataxias",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21727",
            "ConditionBrowseLeafName": "Dyskinesias",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11556",
            "ConditionBrowseLeafName": "Neurologic Manifestations",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4927",
            "ConditionBrowseLeafName": "Cerebellar Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15067",
            "ConditionBrowseLeafName": "Spinal Cord Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21245",
            "ConditionBrowseLeafName": "Heredodegenerative Disorders, Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T5352",
            "ConditionBrowseLeafName": "Spinocerebellar Ataxia",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}